专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO0053633A3 ANTIBODY AND CHEMOKINE CONSTRUCTS THAT ARE DIRECTED TO CCR5, AND THEIR USE FOR TREATING AUTOIMMUNE DISEASES 审中-公开
标题翻译：抗体和趋化因子抗CCR5解决，它们在自身免疫性疾病的治疗
公开(公告)号：WO0053633A3
公开(公告)日：2000-11-16
申请号：PCT/EP0002154
申请日：2000-03-10
申请人： MICROMET AG , MACK MATTHIAS , SCHLOENDORFF DETLEF , BRUEHL HILKE
发明人： MACK MATTHIAS , SCHLOENDORFF DETLEF , BRUEHL HILKE
IPC分类号： C12N15/09 , A61K35/74 , A61K38/00 , A61K39/395 , A61K47/48 , A61P29/00 , A61P37/06 , A61P37/08 , C07K14/47 , C07K16/28 , C07K19/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , A61K38/19 , A61P37/00 , C07K16/46
CPC分类号： A61K47/642
摘要： The invention relates to antibody and chemokine constructs against chemokine receptor expressing cells, especially against monocytes/macrophages expressing the chemokine receptor CCR5 and CCR5 T cells. The invention further relates to the use of antibody and chemokine constructs for destroying cells expressing the chemokine receptor for treating autoimmune diseases and allergic diseases, especially for treating chronic inflammatory diseases of the joints. The inventive antibody and chemokine constructs facilitate the specific depletion of chemokine receptor expressing cells and thus a specific immunosuppressive therapy of autoimmune diseases.
摘要翻译：本发明涉及抗体和趋化因子的构建体针对趋化因子受体表达细胞，特别是对趋化因子受体CCR5表达单核细胞/巨噬细胞和CCR5 <+> T细胞。此外，本发明涉及使用抗体和趋化因子的破坏趋化因子受体表达细胞对自身免疫疾病和过敏性疾病的治疗，特别是用于慢性炎症性关节疾病的治疗。本发明的抗体和趋化因子的构建体使趋化因子受体表达细胞的靶向耗竭并因此自体免疫疾病的选择性免疫抑制治疗。

2. 发明申请

WO0220615A3 ANTIBODY AND/OR CHEMOKINE CONSTRUCTS WHICH BIND TO A CHEMOKINE RECEPTOR AND THEIR USE IN IMMUNOLOGICAL DISORDERS 审中-公开
标题翻译：抗体和/或化学结构与化学受体的结合及其在免疫学疾病中的使用
公开(公告)号：WO0220615A3
公开(公告)日：2002-07-25
申请号：PCT/EP0110433
申请日：2001-09-10
申请人： MICROMET AG , MACK MATTHIAS , SCHLOENDORFF DETLEF , SPRING MICHAEL
发明人： MACK MATTHIAS , SCHLOENDORFF DETLEF , SPRING MICHAEL
IPC分类号： A61K48/00 , A61K31/7088 , A61K35/76 , A61K38/00 , A61K38/19 , A61K39/395 , A61K45/00 , A61K45/06 , A61K47/48 , A61P1/00 , A61P3/10 , A61P13/12 , A61P17/00 , A61P17/06 , A61P19/00 , A61P19/02 , A61P25/00 , A61P29/00 , A61P31/18 , A61P37/02 , A61P37/06 , A61P37/08 , C07K20060101 , C07K14/52 , C07K14/715 , C07K16/28 , C07K19/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C12N15/12 , C12N15/13 , C12N15/62 , C12N15/79 , C12P21/02 , C12P21/08 , C15N5/10
CPC分类号： C07K16/2866 , A61K38/00 , A61K48/00 , A61K2039/505 , C07K14/523 , C07K16/2809 , C07K2317/34 , C07K2317/77 , C07K2319/00
摘要： The present invention relates to the use of an antibody and/or chemokine construct which binds to a chemokine receptor for the preparation of a pharmaceutical composition for the elimination of cells which are latently infected with a primate immunodeficiency virus. In addition, the present invention provides for the use of an antibody and/or chemokine construct which binds to a chemokine receptor for the preparation of a pharmaceutical composition of the treatment, prevention and/or alleviation of inflammatory renal diseases, inflammatory bowel diseases, multiple sclerosis, skin diseases, diabetes or transplant rejection. Furthermore, the invention relates to antibody constructs and/or chemokine constructs wherein said antibody construct comprises a binding site of chemokine receptor 5 and a binding site for CD3 and wherein said chemokine construct comprises RANTES and a toxin. The invention also describes polynucleotides encoding said antibody- or chemokine constructs, and vectors and hosts comprising said nucleic acid molecules. Additionally, the present invention relates to compositions comprising said antibody constructs, chemokine constructs, polynucleotides, vectors and/or hosts. Preferably said composition is a pharmaceutical composition. Described is also the use of antibody constructs, the chemokine constructs, the polynucleotides, the hosts and/or the vectors of the preparation of a pharmaceutical composition and methods for treating, preventing and/or alleviating an immunological disorder or for eliminating latently infected cells, wherein said cells are infected with a primate immunodeficiency virus, like HIV-1. Furthermore, the invention provides for a kit comprising the compounds of the invention.
摘要翻译：本发明涉及结合趋化因子受体的抗体和/或趋化因子构建体用于制备用于消除潜伏感染灵长类动物免疫缺陷病毒的细胞的药物组合物的用途。此外，本发明提供了使用结合趋化因子受体的抗体和/或趋化因子构建体用于制备治疗，预防和/或缓解炎症性肾病，炎性肠病，多发性疾病的药物组合物硬化症，皮肤疾病，糖尿病或移植排斥反应。此外，本发明涉及抗体构建体和/或趋化因子构建体，其中所述抗体构建体包含趋化因子受体5的结合位点和CD3的结合位点，并且其中所述趋化因子构建体包含RANTES和毒素。本发明还描述了编码所述抗体或趋化因子构建体的多核苷酸，以及包含所述核酸分子的载体和宿主。另外，本发明涉及包含所述抗体构建体，趋化因子构建体，多核苷酸，载体和/或宿主的组合物。优选地，所述组合物是药物组合物。还描述了抗体构建体，趋化因子构建体，多核苷酸，制备药物组合物的宿主和/或载体以及用于治疗，预防和/或减轻免疫学障碍或消除潜伏感染的细胞的方法的用途，其中所述细胞被灵长类动物免疫缺陷病毒（如HIV-1）感染。此外，本发明提供了包含本发明化合物的试剂盒。

3. 发明申请

WO0100802A3 PARTIAL SEQUENCES OF THE GENES OF THE PRIMARY AND SECONDARY METABOLISM FROM CORYNEBACTERIUM GLUTAMICUM 审中-公开
标题翻译：部分的序列OFF初级和次级代谢的基因学的谷氨酸棒杆菌的

公开(公告)号：WO0100802A3

公开(公告)日：2001-10-18

申请号：PCT/EP0005853

申请日：2000-06-23

申请人： BASF LYNX BIOSCIENCE AG , MACK MATTHIAS , HERBSTER KARIN

发明人： MACK MATTHIAS , HERBSTER KARIN

IPC分类号： C12N1/21 , C12N15/52 , C07K14/34 , C12N5/10 , C12N15/63 , C12P21/02

CPC分类号： C12N15/52

摘要： The invention relates to methods of producing primary and secondary metabolites using genetically engineered organisms.

摘要翻译：本发明涉及的制造工艺用于使用遗传修饰的生物体初级和次级代谢产物。

5. 发明专利

NO316916B1 未知
公开(公告)号：NO316916B1
公开(公告)日：2004-06-21
申请号：NO20014346
申请日：2001-09-06
申请人： MICROMET AG
发明人： MACK MATTHIAS , SCHLONDORFF DETLEF
IPC分类号： C12N15/09 , A61K35/74 , A61K38/00 , A61K38/19 , A61K39/395 , A61K47/48 , A61P29/00 , A61P37/00 , A61P37/06 , A61P37/08 , C07K14/47 , C07K16/28 , C07K16/46 , C07K19/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10

6. 发明专利

CA2421842A1 ANTIBODY AND/OR CHEMOKINE CONSTRUCTS WHICH BIND TO A CHEMOKINE RECEPTOR AND THEIR USE IN IMMUNOLOGICAL DISORDERS 未知
公开(公告)号：CA2421842A1
公开(公告)日：2002-03-14
申请号：CA2421842
申请日：2001-09-10
申请人： MICROMET AG
发明人： MACK MATTHIAS , SCHLOENDORFF DETLEF , SPRING MICHAEL
IPC分类号： A61K48/00 , A61K31/7088 , A61K35/76 , A61K38/00 , A61K38/19 , A61K39/00 , A61K39/395 , A61K45/00 , A61K45/06 , A61K47/48 , A61P1/00 , A61P3/10 , A61P13/12 , A61P17/00 , A61P17/06 , A61P19/00 , A61P19/02 , A61P25/00 , A61P29/00 , A61P31/18 , A61P37/02 , A61P37/06 , A61P37/08 , C07K20060101 , C07K14/52 , C07K14/715 , C07K16/28 , C07K19/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C12N15/12 , C12N15/13 , C12N15/62 , C12N15/79 , C12P21/02 , C12P21/08
摘要： The present invention relates to the use of an antibody and/or chemokine construct which binds to a chemokine receptor for the preparation of a pharmaceutical composition for the elimination of cells which are latently infected with a primate immunodeficiency virus. In addition, the present invention provides for the use of an antibody and/or chemokine construct whi ch binds to a chemokine receptor for the preparation of a pharmaceutical composition of the treatment, prevention and/or alleviation of inflammatory renal diseases, inflammatory bowel diseases, multiple sclerosis, skin diseases, diabetes or transplant rejection. Furthermore, the invention relat es to antibody constructs and/or chemokine constructs wherein said antibody construct comprises a binding site of chemokine receptor 5 and a binding sit e for CD3 and wherein said chemokine construct comprises RANTES and a toxin. T he invention also describes polynucleotides encoding said antibody- or chemokin e constructs, and vectors and hosts comprising said nucleic acid molecules. Additionally, the present invention relates to compositions comprising said antibody constructs, chemokine constructs, polynucleotides, vectors and/or hosts. Preferably said composition is a pharmaceutical composition. Describe d is also the use of antibody constructs, the chemokine constructs, the polynucleotides, the hosts and/or the vectors of the preparation of a pharmaceutical composition and methods for treating, preventing and/or alleviating an immunological disorder or for eliminating latently infected cells, wherein said cells are infected with a primate immunodeficiency virus , like HIV-1. Furthermore, the invention provides for a kit comprising the compounds of the invention.

7. 发明专利

CA2366713A1 ANTIBODY AND CHEMOKINE CONSTRUCTS AND THEIR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES 未知
公开(公告)号：CA2366713A1
公开(公告)日：2000-09-14
申请号：CA2366713
申请日：2000-03-10
申请人： MICROMET AG
发明人： SCHLONDORFF DETLEF , MACK MATTHIAS
IPC分类号： C12N15/09 , A61K35/74 , A61K38/00 , A61K38/19 , A61K39/395 , A61K47/48 , A61P29/00 , A61P37/00 , A61P37/06 , A61P37/08 , C07K14/47 , C07K16/28 , C07K16/46 , C07K19/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10
摘要： The invention relates to antibody and chemokine constructs against chemokine receptor expressing cells, especially against monocytes/macrophages expressi ng the chemokine receptor CCR5 and CCR5+ T cells. The invention further relates to the use of antibody and chemokine constructs for destroying cells expressing the chemokine receptor for treating autoimmune diseases and allergic diseases, especially for treating chronic inflammatory diseases of the joints. The inventive antibody and chemokine constructs facilitate the specific depletion of chemokine receptor expressing cells and thus a specifi c immunosuppressive therapy of autoimmune diseases.

8. 发明专利

DE60203324D1 未知
公开(公告)号：DE60203324D1
公开(公告)日：2005-04-21
申请号：DE60203324
申请日：2002-12-20
申请人： MICROMET AG
发明人： MACK MATTHIAS , SCHLOENDORFF DETLEF
IPC分类号： A61P29/00 , A61P31/18 , C07K14/52 , C07K16/28 , C07K19/00

9. 发明专利

HU0200484A2 ANTIBODY AND CHEMOKINE CONSTRUCTS THAT ARE DIRECTED TO CCR5, AND THEIR USE FOR TREATING AUTOIMMUNE DISEASES 未知
公开(公告)号：HU0200484A2
公开(公告)日：2002-06-29
申请号：HU0200484
申请日：2000-03-10
申请人： MICROMET AG
发明人： MACK MATTHIAS , SCHLOENDORFF DETLEF
IPC分类号： C12N15/09 , A61K35/74 , A61K38/00 , A61K38/19 , A61K39/395 , A61K47/48 , A61P29/00 , A61P37/00 , A61P37/06 , A61P37/08 , C07K14/47 , C07K16/28 , C07K16/46 , C07K19/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式